Why the study?
Hemostatic and antithrombotic agents are high-risk and costly, and while anticoagulation stewardship importance is recognized, hemostatic stewardship programs remain underutilized.
This review provides a comprehensive toolkit for the development and implementation of combined hemostatic and antithrombotic stewardship programs to improve the quality and cost of care.
Answers are grounded in this paper and cite their sources.
Supports stewardship program adoption to improve care quality and costs; extends observational data but leaves open need for prospective trials.
Hemostatic and antithrombotic agents are high‐risk medications associated with high cost. The importance of anticoagulation stewardship has been recently highlighted by national organizations, but hemostatic stewardship programs remain underutilized. Several established hemostatic and/or antithrombotic stewardship programs have demonstrated a significant impact on the quality and cost of care provided to patients receiving these therapies. This review provides a comprehensive toolkit for development and implementation of combined hemostatic and antithrombotic stewardship programs.
No takes yet. Share an insight, caveat, or question.
Dane et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: